Abstract 174P
Background
Colorectal cancer (CRC) is the second leading cause of cancer deaths, and liver metastasis accounts for most fatalities in CRC patients. Developing more effective treatments for patients with metastatic CRC is an urgent unmet need. Sphingosine kinase 1 (SPHK1) is selectively expressed in tumor-associated macrophages (TAMs) and SPHK1+ TAMs are abundant in metastatic tumor microenvironment. Here, we aimed to reveal the role of SPHK1+ TAMs in regulating immunosuppression and develop novel therapeutic strategies to enhance the efficacy of immune checkpoint blockade (ICB) therapy and mitigate ICB-induced toxicity.
Methods
The expression of SPHK1 in TAMs was determined using laser scanning microscopy and single-cell sequencing databases. The inhibitory effect of SPHK1 blockade alone or combined with ICB on liver metastasis was assessed using an orthotopic mouse model or intrasplenic injection of tumor cells. Flow cytometry and mass cytometry were used to analyze the immune microenvironment in SPHK1-/- knockout mice. The effect of SPHK1 inhibitor PF543 on the ICB-induced toxicity was verified by DSS-induced colitis or humanized mouse model in a combination of ICB. RNA sequencing and western blot were used to further explore the molecular mechanism by which SPHK1 promoted inflammasome activation and IL-1β release.
Results
SPHK1 was selectively expressed by TAMs in CRC, and the abundance of SPHK1+ TAMs was associated with adverse clinical outcomes in CRC patients. In vivo, SPHK1 knockout and inhibition suppressed liver metastasis of CRC and enhanced the anti-tumor activity of ICB. Blocking SPHK1 reduced the infiltration of TAMs and exhausted T cells, and promoted cytotoxicity of CD8+ T cells. Mechanistically, SPHK1/S1P axis led to IL-1β secretion in response to AIM2 and NLRP3 inflammasome activation. SPHK1 inhibitor PF543 and anti-IL-1R alleviated ICB-induced toxicity, including colitis and liver damage. PF543 plus anti-PD-1 therapy could induce complete regression of liver metastasis and mitigate liver dysfunction when further combined with radiotherapy.
Conclusions
Targeting SPHK1 in macrophages could inhibit liver metastasis of CRC and decouple ICB anti-tumor immunity and toxicity.
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (No.82103595).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - Integrated modelling of T cell repertoires to identify clonotype signatures of ICI response
Presenter: Juan Luis Melero
Session: Poster Display
16P - Exosomal PD-L1 and lactate predict clinical outcomes of PD-1 blockade combined with chemotherapy in advanced-stage gastric and gastroesophageal junction adenocarcinoma
Presenter: Yongshun Chen
Session: Poster Display
17P - Spatial Characteristics Associated with the Chemo and Immuno-treatment Response of Gastric Cancer Revealed by Multi-omics Analysis
Presenter: Gang Che
Session: Poster Display
18P - Association of DNA methylation profiles with pathologic complete response in early triple negative breast cancer patients receiving neoadjuvant chemoimmunotherapy
Presenter: Angelika Starzer
Session: Poster Display
19P - The prognostic value of soluble CD73 in advanced triple-negative breast cancer: an exploratory analysis of the SYNERGY trial
Presenter: Denis Zoë
Session: Poster Display
21P - Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE).
Presenter: Alexandre Bertucci
Session: Poster Display
22P - Predictive value of Tertiary Lymphoid Structure in patients with mismatch repair deficient advanced/ recurrent endometrial cancer treated with Dostarlimab.
Presenter: Maria Kfoury
Session: Poster Display
23P - Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma
Presenter: Ronan Flippot
Session: Poster Display
24P - Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC): a hypothesis-generating analysis
Presenter: Matteo Rosellini
Session: Poster Display